RANKL and lymphocyte-mediated bone loss

RANKL 和淋巴细胞介导的骨丢失

基本信息

项目摘要

A decline in estrogen levels, such as occurs at the menopause, causes bone loss by increasing the number of bone resorbing osteoclasts. The mechanisms by which estrogen controls osteoclast number are only partially understood, but previous studies suggest that lymphocytes play an important role. For example, ovariectomy of mice or rats consistently leads to increased numbers of B lymphocytes in the bone marrow. This increase in B cell number has been suggested to contribute to increased osteoclast formation by different mechanisms, such as B cell production of the osteoclastogenic cytokine receptor activator of NF-kappa-B ligand (RANKL) and differentiation of B cell precursors into osteoclasts. However, until recently, there was no functional evidence that B cells play an essential role in ovariectomy-induced bone loss. In studies leading to this application, we have found that production of the cytokine receptor activator of NF-kappa-B ligand (RANKL) by B lymphocytes is essential for the cancellous bone loss caused by estrogen deficiency in mice. Importantly, RANKL is also required for the increase in B cell number that is caused by estrogen deficiency. Also, ovariectomy did not increase the levels of RANKL in B cells in wild type mice. Together, these results suggest that it is the increase in B cell number that is required for ovariectomy-induced bone loss in this model. It is also important to note that deletion of RANKL from B cells did not prevent loss of cortical bone caused by estrogen deficiency. Therefore, RANKL produced by cell types other than B cells must be involved in the osteoclast formation in this skeletal compartment. Based on these results, we hypothesize that loss of estrogen causes cancellous bone loss, in part, by increasing the number of B cells, which can then act as osteoclast progenitors. Further, we propose that loss of estrogen causes cortical bone loss by altering production of RANKL by cells of the osteoblast lineage. To address these hypotheses, lineage-tracing studies will be performed to determine whether B cells, at any stage of their development, can differentiate into bone resorbing osteoclasts in vivo. In addition, whether estrogen suppresses B cell number by acting directly on these cells will be determined by conditional deletion of estrogen receptor alpha from this cell type. Lastly, mice in which the RANKL gene has been deleted from either osteocytes or from stromal cells of the osteoblast lineage will be ovariectomized to determine whether RANKL produced by these cell types contributes to the cortical bone loss caused by estrogen deficiency.
雌激素水平的下降,如发生在绝经期,通过增加骨质疏松症, 骨吸收破骨细胞的数量。雌激素控制的机制 破骨细胞的数量只有部分了解,但以前的研究表明,淋巴细胞, 发挥重要作用。例如,小鼠或大鼠的卵巢切除术一致地导致增加的 骨髓中B淋巴细胞的数量。这种B细胞数量的增加, 提示通过不同机制促进破骨细胞形成,如B NF-κ-B配体的破骨细胞生成细胞因子受体激活剂的细胞产生 (RANKL)和B细胞前体向破骨细胞的分化。然而,直到最近, 没有功能性证据表明B细胞在卵巢切除术诱导的骨丢失中起重要作用。 在导致这种应用的研究中,我们发现细胞因子受体的产生 由B淋巴细胞激活的NF-κ-B配体(RANKL)对松质骨是必需的 雌激素缺乏引起的小鼠体内雌激素的减少。重要的是,RANKL也是 由雌激素缺乏引起的B细胞数量增加。此外,卵巢切除术并没有 增加野生型小鼠B细胞中RANKL的水平。这些结果表明, 是该模型中卵巢切除术诱导的骨丢失所需的B细胞数量的增加。 同样重要的是要注意,从B细胞中删除RANKL并不能防止皮质骨丢失。 由于雌激素缺乏引起的骨质疏松。因此,由除B细胞类型以外的细胞类型产生的RANKL 细胞必须参与该骨骼隔室中破骨细胞的形成。基于这些 结果,我们假设雌激素的丢失导致松质骨丢失,部分是通过增加 B细胞的数量,然后可以作为破骨细胞祖细胞。此外,我们建议, 雌激素的丢失通过改变骨组织细胞RANKL的产生而引起皮质骨丢失。 成骨细胞谱系。为了解决这些假设,将进行谱系追踪研究, 确定B细胞在其发育的任何阶段是否可以分化成骨 体内再吸收破骨细胞。此外,雌激素是否通过作用于B细胞抑制B细胞数量, 直接在这些细胞上的雌激素受体α的条件性缺失将通过从 这种细胞类型。最后,RANKL基因已从骨细胞或骨髓细胞中删除的小鼠, 从成骨细胞谱系的基质细胞中提取的RANKL将被卵巢切除,以确定RANKL是否 由这些细胞类型产生的雌激素会导致皮质骨丢失 缺陷

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHARLES A O'BRIEN其他文献

CHARLES A O'BRIEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHARLES A O'BRIEN', 18)}}的其他基金

Genetic Models
遗传模型
  • 批准号:
    10357774
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10117260
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Center for Musculoskeletal Disease Research (CMDR)
肌肉骨骼疾病研究中心 (CMDR)
  • 批准号:
    10357772
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10357773
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Genetic Models
遗传模型
  • 批准号:
    10117261
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10495742
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Center for Musculoskeletal Disease Research (CMDR)
肌肉骨骼疾病研究中心 (CMDR)
  • 批准号:
    10495741
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Center for Musculoskeletal Disease Research (CMDR)
肌肉骨骼疾病研究中心 (CMDR)
  • 批准号:
    10117257
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
RANKL and lymphocyte-mediated bone loss
RANKL 和淋巴细胞介导的骨丢失
  • 批准号:
    9275307
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
RANKL and Inflammation-associated Bone Loss
RANKL 和炎症相关的骨丢失
  • 批准号:
    8258635
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了